A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
Price : $35 *
At a glance
- Drugs ReN 001 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms PISCES; PISCES I
- Sponsors ReNeuron
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2018 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2023.
- 04 Oct 2016 Results were published in The Lancet.